IMFINZI AstraZeneca Pty Ltd
Product name
IMFINZI
Sponsor
Accepted date
Aug-2024
Active ingredients
durvalumab
Proposed indication
For the treatment of patients with limited-stage small cell lung cancer.
Application type
C (new indication)
Publication date
Aug-2024
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.